What's Next for Sotorasib in NSCLC?

Area of Science:

• Oncology
• Pharmacology

Background:

• Non-small cell lung cancer (NSCLC) treatment often involves chemotherapy.
• Targeted therapies are emerging for specific genetic mutations.

Purpose of the Study:

• To compare the efficacy and safety of sotorasib versus docetaxel in patients with KRAS G12C-mutated NSCLC.
• To evaluate disease progression, death, and overall survival outcomes.

Main Methods:

• The CodeBreaK 200 trial was a randomized, open-label study.
• Patients received either sotorasib or docetaxel.

Main Results:

• Sotorasib demonstrated a 34% relative risk reduction in disease progression or death compared to docetaxel.
• No significant improvement in overall survival was observed with sotorasib.
• Sotorasib exhibited a more favorable toxicity profile.

Conclusions:

• Sotorasib offers a survival benefit in terms of progression-free survival and reduced toxicity compared to docetaxel for KRAS G12C-mutated NSCLC.
• Further research, including subgroup analyses and combination therapies, is warranted to optimize KRAS inhibitor treatment.